Updating ...
Home
About Us
Journal History
Submission Fee
Abstracting And Indexing
Copyright
Digital Archiving and Preservation Policy
Aims and Scope
Editorial Board
Instructions to Authors
Instructions to Authors
Manuscript Preparation
Ethical Policy
Contact Us
EJBH - Study group
Archive
Author Index
Turkish Federation of Breast Diseases Societies
Archive
Author Index
Turkish Federation of Breast Diseases Societies
E-ISSN:2587-0831
Toggle navigation
Home
About Us
Journal History
Submission Fee
Abstracting And Indexing
Copyright
Digital Archiving and Preservation Policy
Aims and Scope
Editorial Board
Instructions to Authors
Instructions to Authors
Manuscript Preparation
Ethical Policy
Contact Us
EJBH - Study group
Review
HOW SHOULD BE THE SURGICAL APPROACH TO HER2 POSITIVE BREAST CANCER?
Can Atalay
Eur J Breast Health 2010; 6: 1-4
Full
Text
PDF
Read
Importance of HER2/NEU (C-ERB-B2) Status in Breast Cancer: Which Method is More Effective to Evaluate of HER-2 Status?
Nuket Eliyatkın
Baha Zengel
Safiye Aktaş
Eur J Breast Health 2013; 9: 175-181
DOI: 10.5152/tjbh.2013.28
Full
Text
PDF
Read
Original Article
Problems In Determining Her2 Status In Breast Carcinoma
Emel Ebru Pala
Ümit Bayol
Alp Özgüzer
Ülkü Küçük
Çağlar Yıldız Akdeniz
Özlem Sezer
Eur J Breast Health 2015; 11: 10-16
DOI: 10.5152/tjbh.2014.2103
Full
Text
PDF
Read
Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report
Umut Varol
Burcu Çakar
İbrahim Yıldız
Ceyda Tunakan Dalgıç
Hatice Özışık
Melih Özışık
Burçak Karaca
Bülent Karabulut
Rüçhan Uslu
Eur J Breast Health 2014; 10: 42-46
DOI: 10.5152/tjbh.2014.1773
Full
Text
PDF
Read
An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
İrfan Cicin
Mohammed Oukkal
Hassen Mahfouf
Amel Mezlini
Blaha Larbaoui
Slim Ben Ahmed
Hassan Errihani
Khalid Alsaleh
Rhizlane Belbaraka
Perran Fulden Yumuk
Burce Goktas
Mustafa Özgüroğlu
Eur J Breast Health 2022; 18: 63-73
DOI: 10.4274/ejbh.galenos.2021.2021-9-9
PMID:35059593
Full
Text
PDF
Read
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in cN0 Breast Cancer: Impact of HER2-Positive Status on Survival
Juan Alors-Ruiz
Salomé Sanz-Viedma
Francisco Javier Fernández-Garcia
Francisco Sendra-Portero
Eur J Breast Health 2024; 20: 94-101
DOI: 10.4274/ejbh.galenos.2024.2023-11-3
Full
Text
PDF
Read
The Correlation of Magee Equations
TM
and Oncotype DX
®
Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
Atilla Soran
Kaori Tane
Efe Sezgin
Rohit Bhargava
Eur J Breast Health 2020; 16: 117-123
DOI: 10.5152/ejbh.2020.5338
Full
Text
PDF
Read
Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers
Melek Ünçel
Gülden Diniz
Gamze Aköz
Zübeyde Yıldırım Ekin
Sevil Sayhan
Serdar Yardım
Semra Salimoğlu
Eur J Breast Health 2019; 15: 125-129
DOI: 10.5152/ejbh.2019.4677
Full
Text
PDF
Read
Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy
Hongxia Sun
Hui Chen
James Crespo
Guilin Tang
Melissa Robinson
Bora Lim
Ayşegül A. Şahin
Eur J Breast Health 2021; 17: 128-136
DOI: 10.4274/ejbh.galenos.2021.2021-2-9
PMID:33870112
Full
Text
PDF
Read
Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine
İzzet Doğan
Nail Paksoy
Naziye Ak
Sezai Vatansever
Pınar Saip
Adnan Aydıner
Eur J Breast Health 2023; 19: 128-133
DOI: 10.4274/ejbh.galenos.2023.2022-12-4
PMID:37025570
Full
Text
PDF
Read
Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study
Tülay Canda
Ekrem Yavuz
Necmettin Özdemir
Sennur İlvan
Serpil Sak Dizbay
Merih Güray Durak
Sıtkı Tuzlalı
Osman Zekioğlu
Atakan Demir
Handan Onur
Kasım Üstündağ
Burçe Göktaş
Eur J Breast Health 2018; 14: 160-165
DOI: 10.5152/ejbh.2018.3961
Full
Text
PDF
Read
The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
Stephane Thibodeau
Ioannis A. Voutsadakis
Eur J Breast Health 2019; 15: 163-170
DOI: 10.5152/ejbh.2019.4901
Full
Text
PDF
Read
Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR
Ramesh Omranipour
Roghiyeh Jalili
Adel Yazdankhahkenary
Abdolali Assarian
Mehrzad Mirzania
Bita Eslami
Eur J Breast Health 2020; 16: 213-218
DOI: 10.5152/ejbh.2020.5487
Full
Text
PDF
Read
Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study
Damiano Gentile
Andrea Sagona
Ruggero Spoto
Davide Franceschini
Stefano Vaccari
Valeriano Vinci
Ersilia Biondi
Lorenzo Scardina
Corrado Tinterri
Eur J Breast Health 2022; 18: 315-322
DOI: 10.4274/ejbh.galenos.2022.2022-5-3
PMID:36248756
Full
Text
PDF
Read
Case Report
Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
Bülent Karagöz
Alpaslan Özgün
Levent Emirzeoğlu
Tolga Tunçel
Serkan Çelik
Oğuz Bilgi
Kemal Kara
Eur J Breast Health 2015; 11: 48-51
DOI: 10.5152/tjbh.2014.2009
Full
Text
PDF
Read
RECURRENT SUPRAVENTRICULAR TACHYCARDIA ASSOCIATED WITH LAPATINIB: A CASE REPORT OF A PROBABLE CARDIAC ADVERSE EFFECT
Özgür Tanrıverdi
Nezih Meydan
Sabri Barutca
Eur J Breast Health 2011; 7: 188-190
Full
Text
PDF
Read
Advanced Search
About Journal
Article Tools
Subscribe
×
×
Subscribe
Full Name
E-mail